1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.
2.Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245–55.
3.Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010; 10:9–22.
4.Carrasco-Garcia E, Auzmendi-Iriarte J, Matheu A. Integrin alpha7: a novel promising target in glioblastoma stem cells. Stem Cell Investig. 2018; 5:2.
5.Ming XY, Fu L, Zhang LY, Qin YR, Cao TT, Chan KW et al. Integrin alpha7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma. Nat Commun. 2016; 7:13568.
6.Hsu YL, Hung JY, Liang YY, Lin YS, Tsai MJ, Chou SH et al. S100P interacts with integrin alpha7 and increases cancer cell migration and invasion in lung cancer. Oncotarget. 2015; 6:29585–98.
7.Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002; 110:673–87.
8.Tan LZ, Song Y, Nelson J, Yu YP, Luo JH. Integrin alpha7 binds tissue inhibitor of metalloproteinase 3 to suppress growth of prostate cancer cells. Am J Pathol. 2013; 183:831–40.
9.Nunes AM, Barraza-Flores P, Smith CR, Burkin DJ. Integrin alpha7: a major driver and therapeutic target for glioblastoma malignancy. Stem Cell Investig. 2017; 4:97.
10.Burkin DJ, Fontelonga TM. Mesothelioma cells breaking bad: loss of integrin alpha7 promotes cell motility and poor clinical outcomes in patients. J Pathol. 2015; 237:282–4.
11.Haas TL, Sciuto MR, Brunetto L, Valvo C, Signore M, Fiori ME et al. Integrin alpha7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. Cell Stem Cell. 2017; 21:35–50 e9.
12.Ren B, Yu YP, Tseng GC, Wu C, Chen K, Rao UN et al. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst. 2007; 99:868–80.
13.Gyuris J, Golemis E, Chertkov H, Brent R. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell. 1993; 75:791–803.
14.Hannon GJ, Casso D, Beach D. KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc Natl Acad Sci U S A. 1994; 91:1731–5.
15.Kawashima T, Hirose K, Satoh T, Kaneko A, Ikeda Y, Kaziro Y et al. MgcRacGAP is involved in the control of growth and differentiation of hematopoietic cells. Blood. 2000; 96:2116–24.
16.Brabletz T. EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell. 2012; 22:699–701.
17.Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704–15.
18.Zou J, Li H, Huang Q, Liu X, Qi X, Wang Y et al. Dopamine-induced SULT1A3/4 promotes EMT and cancer stemness in hepatocellular carcinoma. Tumour Biol. 2017; 39:1010428317719272.
19.Santamaria PG, Moreno-Bueno G, Portillo F, Cano A. EMT: Present and future in clinical oncology. Mol Oncol. 2017; 11:718–38.
20.Nistico P, Bissell MJ, Radisky DC. Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol. 2012; 4.
21.Gaianigo N, Melisi D, Carbone C. EMT and Treatment Resistance in Pancreatic Cancer. Cancers (Basel). 2017; 9.